Brenipatide: once-monthly weight-loss & diabetes drug (LY3537031)
An experimental injectable drug by Eli Lilly that activates two gut hormones at once to control blood sugar and reduce weight, dosed just once a month; not yet an approved drug.
- Class
- Dual GIP/GLP-1 receptor agonist (incretin mimetic), once-monthly formulation
- Status
- Investigational — no FDA, EMA, or equivalent approval for any indication
- Best-supported effect
- Mechanistic plausibility for metabolic and reward-circuit modulation based on GIP/GLP-1 receptor class evidence and indirect tirzepatide rodent data; no brenipatide-specific efficacy data published
- Main caveat
- Every claim about brenipatide rests on trial design and analog evidence, not published trial results; active Phase 3 programs exist but no efficacy or safety data has been reported as of early 2026
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Brenipatide (also known as LY3537031) is an investigational drug developed by Eli Lilly that activates two hormone receptors simultaneously — the GIP receptor and the GLP-1 receptor — making it a dual incretin agonist in the same class as tirzepatide. What sets brenipatide apart from other drugs in this class is its duration: a structural backbone change (a tryptophan residue replaced by alpha-methyl-tyrosine) gives the molecule greater resistance to enzymatic breakdown, enabling once-monthly subcutaneous dosing rather than the once-weekly schedule required by tirzepatide, semaglutide, and other incretin agents.
Equally notable is what Lilly is primarily testing it for. Rather than leading with obesity or diabetes — the usual entry points for incretin drugs — brenipatide's most prominent active trials target alcohol use disorder and bipolar disorder, conditions where GIP and GLP-1 receptor signaling is proposed to modulate dopamine reward circuits. Earlier-phase studies are also running in smoking cessation, asthma, obesity, and cardiovascular and liver disease.
As of early 2026, no efficacy or safety results from any brenipatide trial have been published. The compound is available only through active clinical trial enrollment and has no approved indication in any jurisdiction.
History
Brenipatide emerged from the same Eli Lilly metabolic-peptide research program that produced tirzepatide (approved as Mounjaro and Zepbound) and retatrutide. Following tirzepatide's commercial and clinical success with dual GIP/GLP-1 agonism on a weekly schedule, Lilly developed brenipatide as an extended-duration next-generation candidate — engineering the alpha-methyl-tyrosine substitution to confer enzymatic resistance and push the dosing interval to once monthly. The most clinically distinctive decision was the lead indication strategy: rather than entering the crowded weekly-incretin obesity and diabetes space, the program's most prominent Phase 3 trials address alcohol use disorder and bipolar disorder, reflecting growing translational interest in GLP-1 and dual incretin receptor effects on central reward circuitry.
What it does
Brenipatide activates the same two receptors as tirzepatide. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. GIP receptor activation contributes insulin-sensitizing and lipolytic signaling. The once-monthly pharmacokinetic profile means drug levels remain sustained across the full dosing interval — unlike weekly agents, the drug cannot be rapidly cleared if it needs to be stopped.
Beyond the established metabolic effects of the class, the neuropsychiatric development rationale rests on preclinical evidence that GLP-1 receptor signaling dampens reward circuit activity — through GABAergic inhibition of projections from the paraventricular nucleus to the ventral tegmental area and through modulation of VTA dopaminergic neurons. GIP receptor activation is proposed to promote synaptic plasticity via PI3K/AKT/mTOR signaling, which may strengthen inhibitory control over reward-seeking behavior. Importantly, the preclinical reward-circuit evidence that informs these hypotheses comes from studies of tirzepatide, not brenipatide directly — the compounds are related dual GIP/GLP-1 agonists but structurally distinct.
Evidence
- Human: No efficacy or safety results from any brenipatide trial have been published. Active Phase 3 trials are running for alcohol use disorder (RENEW-ALC-1, approximately 1,100 participants) and bipolar disorder. Phase 2 trials are running for asthma and smoking cessation. Phase 1 studies cover metabolic, cardiovascular, and liver disease indications including obesity. No results are expected to be in the public record before RENEW-ALC-1 reports.
- Animal: No published preclinical data specific to brenipatide has been identified. The mechanistic rationale for addiction and neuropsychiatric indications draws on rodent work with tirzepatide — a structurally related dual GIP/GLP-1 agonist — which showed attenuation of alcohol-induced dopamine signaling and dose-dependent reductions in voluntary alcohol consumption in rodent models. This constitutes indirect class-level biological plausibility, not brenipatide-specific efficacy evidence.
- In vitro: No brenipatide-specific cell or binding assay data has been identified.
Known effects
- Dual GIP/GLP-1 receptor agonism — Mechanistic (class-based; brenipatide-specific binding data not individually reported in public literature)
- Once-monthly subcutaneous pharmacokinetics — Structural/pharmacokinetic design claim; no published PK data for brenipatide specifically
- Metabolic effects (weight loss, glucose control) — Mechanistic / Phase 1 studies active; no efficacy results published
- Alcohol use disorder — Phase 3 (RENEW-ALC-1 active, no results published)
- Bipolar disorder — Phase 3 (active, no results published)
- Smoking cessation, asthma — Phase 2 (active, no results published)
Safety signals
No published safety data specific to brenipatide exists. The following signals are class-level considerations drawn from the broader GIP/GLP-1 receptor agonist literature:
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are the most characteristic adverse effects of the incretin drug class and are expected with brenipatide. A distinctive pharmacokinetic concern specific to monthly dosing is the slow offset of adverse effects — because drug levels remain sustained for weeks after injection, adverse effects cannot be rapidly reversed by discontinuation, unlike with weekly agents.
By analogy with GLP-1 receptor agonists as a class, thyroid C-cell tumors have been observed in rodents at supratherapeutic doses (relevance to humans is unestablished), and pancreatitis is a class-level monitoring consideration. Additive hypoglycemia risk is expected in patients with diabetes receiving insulin or insulin secretagogues concurrently.
The long-term safety profile of brenipatide specifically is entirely unknown. All safety data from ongoing trials is unpublished.
Regulatory status
- US (FDA): Not approved. Investigational only — available exclusively through active Eli Lilly clinical trial enrollment. No commercial, prescription, or compounding supply exists.
- EU / International: No marketing authorization in any major jurisdiction. International access is through approved trial enrollment only.
- WADA: Not listed by name on the WADA Prohibited List. The S0 category covers substances not approved by any governmental health authority for human therapeutic use, which describes brenipatide as of early 2026. Athletes subject to anti-doping testing should treat it as prohibited.
Mechanism
Brenipatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — the same mechanistic class as tirzepatide. GLP-1R agonism drives glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite reduction; GIPR agonism contributes insulin sensitization and promotes lipolysis. The defining structural feature is a tryptophan-to-alpha-methyl-tyrosine substitution that confers resistance to enzymatic degradation, producing a half-life sufficient for once-monthly subcutaneous administration.
For the neuropsychiatric indications, the proposed mechanism is GLP-1R-mediated dampening of reward circuitry: activation of GLP-1 receptors is reported to reduce signaling through alpha-MSH-driven GABAergic projections from the paraventricular nucleus to the ventral tegmental area, and to directly modulate VTA dopaminergic neurons. GIPR activation is proposed to enhance PI3K/AKT/mTOR-mediated synaptic plasticity, potentially strengthening inhibitory control over reward-seeking behavior. These pathway-level hypotheses are supported by rodent studies with tirzepatide, not brenipatide-specific data — whether the mechanism applies equivalently to brenipatide in humans is the central question RENEW-ALC-1 is designed to test.
The full amino acid sequence of brenipatide and its published pharmacokinetic parameters (half-life, volume of distribution, dose-response) are not in the public record as of early 2026.
Open questions
- All efficacy endpoints are unpublished. The core clinical questions — whether brenipatide reduces heavy drinking days in AUD, produces measurable benefit in bipolar disorder, or generates weight loss comparable to weekly dual agonists — cannot be answered until trial results are reported.
- Adverse effect management with monthly dosing. Because drug levels persist for weeks after injection, management of class GI adverse effects and any emerging safety signals is qualitatively different from weekly incretin agents. Trial protocols presumably address this through titration and monitoring; published safety management data are absent.
- Translation from tirzepatide preclinical data. The reward-circuit preclinical rationale derives from studies of tirzepatide, a structurally distinct molecule. Whether findings translate to brenipatide, given the alpha-methyl-tyrosine modification and different pharmacokinetics, is unestablished.
- Bipolar disorder mechanism. The mechanistic basis for any potential benefit in bipolar disorder — whether from mood effects, metabolic comorbidity management, or both — has not been characterized.
- Comparative efficacy vs weekly incretin agents. No head-to-head trial data against tirzepatide or other weekly dual agonists exists. The convenience trade-off of monthly dosing versus reduced dose-adjustment flexibility is unstudied.
- Published pharmacokinetics. Half-life, dose-response relationships, and volume of distribution for brenipatide have not been reported in the public literature.
Related peptides
- Tirzepatide — the approved weekly dual GIP/GLP-1 agonist from the same Lilly program; the closest structural and mechanistic reference for brenipatide's expected effects
- Retatrutide — Lilly's triple GIP/GLP-1/glucagon agonist; another next-generation incretin in advanced development from the same pipeline
- Semaglutide — the leading weekly GLP-1 agonist (Ozempic, Wegovy); single-receptor reference point for the GLP-1 component of brenipatide's mechanism
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does activating both the GIP and GLP-1 receptors together work better than activating either alone for reducing the urge to drink alcohol?
If true, brenipatide could become the first fundamentally new type of treatment for alcohol addiction in decades, potentially helping millions of people for whom current medications do not work well enough.
Because brenipatide is given once monthly, could the drug's effective action on its two targets change significantly between the injection and the end of the month?
Understanding this shift would help doctors time activity monitoring, food intake assessments, or psychiatric symptom evaluations to the right point in the monthly cycle, potentially explaining why some patients respond better than others depending on how rigidly they follow the dosing schedule.
▸3-letter notation
▸citationbibtex
@peptide{pep10969,
sequence = {CYFQNCPRGX},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}